INTRODUCTION:Diabetes mellitus is the leading disorder in India. Thiazolidinediones have been marketed since 1997 and are effective glucose lowering drugs, but individual drugs of this category like Pioglitazone have been linked to serious side effects like bladder cancer and hence banned in India.  OBJECTIVES: A survey was conducted to evaluate the prescription trends of type II diabetes in Mumbai, India and the adverse drug reactions associated with it. To evaluate the effect of sales of pioglitazone after its ban was removed. To observe the variation in prescription trends as compared to normal trends in case of drug resistance. METHODS: Two sets of questionnaires were prepared which captured patient demographics, prescription trends and adverse drug reactions of type II diabetes patients in Mumbai, India.The questionnaires targeted 75 drug stores, 40 General Practitioners and 3 government hospitals. RESULTS: Average number of prescriptions received by the pharmacist under the survey were 30-40 per week. Males are more affected than females. The trend of prescriptions prescribed by the general practitioners is similar to that of prescriptions received by the drug stores. Metformin is majorly prescribed followed by Glimepiride, Voglibose, Pioglitazone. Contrasting results were obtained with respect to Pioglitazone on comparing the prescription trends of doctors to the pharmacists as it was often prescribed by doctors after its ban was removed  but its sales had not increased. The most number of   adverse reactions were shown by Metformin and Glimepiride followed by Pioglitazone,Gliptins and Incretin Mimetics showed minimum side effects. CONCLUSIONS: From our results it was observed that there was no increase in the sales of Pioglitazone. Patients were treated with Metformin and Metformin-Glimepiride combination as first line treatment. Pioglitazone and insulin are most commonly prescribed in case of a drug resistance. Dose variations were suggested by general practitioners in case of a drug resistance.